Laboratorios Farmaceuticos Rovi, S.A. (LABFF) Stock

About Laboratorios Farmaceuticos Rovi, S.A.

Laboratorios Farmaceuticos Rovi, S.A. is a pharmaceutical firm actively involved in the discovery, creation, manufacturing, and commercialization of medicinal products. Its market presence extends across Spain, the European Union, OECD nations, and other international territories. Beyond its proprietary portfolio, Rovi also distributes pharmaceutical offerings under license from other companies. Rovi's diverse product lineup addresses several critical health conditions. Key offerings include Hibor and Becat (an Enoxaparin biosimilar), both low-molecular-weight heparins employed in preventing and managing venous thromboembolic disorders. Neparvis targets symptomatic chronic heart failure with reduced ejection fraction in adults. For hypercholesterolemia, the company offers Absorcol, Vytorin, and Orvatez. Respiratory ailments like chronic obstructive pulmonary diseases (COPD) are treated with long-acting bronchodilators such as Hirobriz Breezhaler and Ulunar Breezhaler. Volutsa is prescribed for men experiencing moderate to severe storage and voiding symptoms due to benign prostatic hyperplasia (BPH) who have not responded sufficiently to single-drug therapies. Additionally, Medikinet and Medicebrán provide treatment for attention deficit hyperactivity disorder (ADHD) in pediatric and adolescent populations. The firm also supplies a range of specialized hospital products for diagnostic imaging. These include contrast agents like Iomeron and Iopamiro for CT scans and interventional procedures, Multihance and Prohance for MRI, and Sonovue for ultrasound examinations. Furthermore, Rovi provides advanced contrast injection systems, including EmpowerCTA+, EmpowerMR, and CT Exprès, along with their associated disposable components. Its portfolio extends to over-the-counter (OTC) pharmaceutical products. Moreover, Rovi offers contract development and manufacturing organization (CDMO) services to external businesses, producing pharmaceuticals in diverse forms such as prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. Rovi caters to a broad spectrum of healthcare stakeholders, encompassing wholesalers, physicians, nurses, pharmacists, and directly, patients. A notable partnership exists with Moderna, Inc., where Rovi is involved in the manufacturing of mRNA COVID-19 vaccine candidates. Established in 1946 and headquartered in Madrid, Spain, Laboratorios Farmaceuticos Rovi, S.A. operates as a subsidiary of Norbel Inversiones, S.L.

Laboratorios Farmaceuticos Rovi, S.A. is headquartered in ES.

Laboratorios Farmaceuticos Rovi, S.A. (LABFF) stock trades at $67.17 with a market capitalization of $3.44B. The stock is valued at a price-to-earnings (P/E) ratio of 16.22, price-to-book of 4.29, price-to-sales of 3.88. Over the past 52 weeks the stock has ranged between $67.17 and $90.61, and currently trades 25.9% below its 52-week high. It pays a dividend yielding 1.64%.

On profitability, Laboratorios Farmaceuticos Rovi, S.A. generates a return on equity (ROE) of 27.84% — well above the market average, a sign of a high-quality business, return on capital employed of 19.97%, an operating margin of 21.97%, a net profit margin of 23.95%.

Official website: www.rovi.es